Companion animal vaccines are substances that are used to stimulate the production of antibodies and provide immunity against one or several diseases in pets such as dogs, birds, and cats. They are also used to improve food digestion, enhance immunity, enable animals to gain fat and weight, and generate good quality meat that is harvested for commercial purposes. The main products of companion animal veterinary vaccines are inactivated, live attenuated, recombinant, and other products. A recombinant vaccine is one that was created using recombinant DNA technology. This entails inserting DNA encoding an antigen (such as a bacterial surface protein) that triggers an immunological response into bacterial or mammalian cells, expressing the antigen in these cells, and then purifying it from them. The products are administered through oral, parenteral, and other routes of administration and are distributed through veterinary hospitals, veterinary clinics, pharmacies, drug stores, and other distribution channels. The companion animal veterinary vaccines research report is one of a series of new reports from The Business Research Company that provides companion animal veterinary vaccines statistics, including companion animal veterinary vaccines industry global market size, regional shares, competitors with companion animal veterinary vaccines share, detailed companion animal veterinary vaccines segments, market trends and opportunities, and any further data you may need to thrive in the companion animal veterinary vaccines industry. This companion animal veterinary vaccines research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global companion animal veterinary vaccines market size will grow from $3.25 billion in 2022 to $3.47 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global companion animal veterinary vaccines market size is expected to grow to $4.48 billion in 2027 at a CAGR of 6.6%. Increased pet ownership by Gen X and Gen Y adults contributed to the growth of the companion animal veterinary vaccine market during the historic period. According to the APPA, millennials, or Gen Y, represent the largest segment of pet owners for all types of pets. More than 80% of Gen Y and Gen Z own a dog, and 50% or less own a cat as a pet. Multiple pet ownership is also on the rise in some parts of the world. According to the 2019-2020 APPA National Pet Owners Survey, 67% of US households own pets, which is equal to 84.9 million homes. Pet owners are well aware of advanced facilities and are willing to spend a large amount of money on the health of their pets. Therefore, the rise in pet ownership aids in the growth of the companion animal veterinary vaccine market. The high cost of veterinary vaccines is expected to restrain the growth of the market. According to data from Harris Interactive, in the USA, households with pets spend about $1,000 on pet care. There are around 70% of households in the USA who own a pet and only 39% have enough in their savings to cover high spending related to pet care. According to a report by PET IQ, in the USA, nearly 28% of households experienced barriers to veterinary care in the past two years. 80% of pet owners are unable to obtain preventative care due to financial constraints. There are several instances when it happens that the pet owners cannot afford expensive animal treatment and this factor restrained the growth of the companion animal veterinary vaccines market. Usually, the average cost of the rabies vaccine varies, typically from about $1,200 to $6,500. Thus, the high cost of companion animal veterinary vaccines will restrain the growth of the market over the forecast period. Companies in the companion animal veterinary vaccine industry are increasingly collaborating and partnering with other players to drive product innovations. To succeed in the increasingly competitive veterinary market, companion animal veterinary vaccine companies are entering into new geographies and developing innovative products through sharing skills and expertise with other players. For instance, Merck & Co.’s subsidiary MSD Animal Health announced a strategic partnership with Vinovo B.V., a division of Viscon Hatchery Automation, the leading hatchery automation company, to provide a new standard in safe and effective Vinovo vaccination to improve bird welfare and reduce vaccine reactions. In February 2020, Zoetis, Inc., a US-based animal health company specializing in the discovery, development, production, and marketing of animal health drugs, acquired Ethos Diagnostic Science for an undisclosed amount. Through this acquisition, Zoetis continues to expand its diagnostics presence in order to provide American veterinarians with comprehensive services at an improved value. Ethos Diagnostic Science is a US-based veterinary diagnostic company pioneering in various types of diagnostic testing and clinical chemistry. Major players in the companion animal veterinary vaccines market are Boehringer Ingelheim, Eli Lilly and Company (Elcano), Heska Co., Merck Animal Health, Virbac, Zoetis, ElancoCevaSante Animal S.A., Bayer Healthcare, NEOGEN CORPORATION, and ImmuCell Corporation. North America was the largest region in the companion animal veterinary vaccines market in 2022. Asia-Pacific was the second-largest region in the global companion animal veterinary vaccines market. The regions covered in the global companion animal veterinary vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the companion animal veterinary vaccines market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The companion animal veterinary vaccine market consists of sales of toxoid vaccines, viral vector vaccines, messenger RNA vaccines, and conjugated vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global companion animal veterinary vaccines market is segmented - 1) By Product: Inactivated, Live Attenuated, Recombinant, Other Products 2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 3) By Distribution Channel: Veterinary Hospitals, Veterinary Clinics, Pharmacies And Drug Stores, Other Distribution Channels

Animal medicines refer to a collective term for drugs and therapies, including veterinary vaccines, veterinary antibiotics, and other veterinary pharmaceuticals, that are used to treat animal diseases to improve animals’ performance and health by identifying disease symptoms and drugs for the cure of illness. The main types of animal medicines are veterinary pharmaceuticals and feed additives, which are used for livestock and companion animals. Veterinary pharmaceuticals refer to animal medicine that is given to animals for treating diseases. Animal medicine is used by veterinary hospitals, pharmacies, drug stores, and veterinary clinics. The animal medicine research report is one of a series of new reports from The Business Research Company that provides animal medicine statistics, including animal medicine industry global market size, regional shares, competitors with animal medicine shares, detailed animal medicine segments, market trends and opportunities, and any further data you may need to thrive in the animal medicine industry. This animal medicine research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global animal medicine market grew from $46.91 billion in 2022 to $50.47 billion in 2023 at a compound annual growth rate (CAGR) of 7.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, and affecting many markets across the globe. The animal medicine market is expected to grow from $65.12 billion in 2027 at a CAGR of 6.6%. The increasing penetration of pet insurance is expected to drive the animal medicine market. Globally, the pet insurance market is largely untapped with extremely low penetration rates, providing a large market opportunity. In developed economies such as the USA, the pet insurance penetration rate is around 1%, although in Western European countries such as the UK, the penetration rate is around 20%. During the forecast period, the pet insurance market in the USA is expected to grow by $2 billion in 2022, at a compound annual growth rate of 14%, mainly driven by the increasing consumer awareness and rising disposable income of companion animal owners. Increasing penetration of pet insurance will increase the number of visits at veterinary clinics supporting the use of animal medicine in the treatment of different diseases The outbreak of COVID-19 disease (COVID-19) has acted as a massive restraint on the animal medicine market in 2020 as supply chains were disrupted due to trade restrictions and consumption declined due to lockdowns imposed by governments globally. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China, and has spread globally, including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of "lock down" and the outbreak hurting businesses throughout 2020 and into 2021. However, it is expected that the animal medicine market will recover from the shock over the forecast period as it is a "black swan" event and not related to ongoing or fundamental weaknesses in the market or the global economy. Nanotechnology is increasingly gaining traction in the animal medicine market as a substitute for veterinary antibiotics. Nanotechnology is the study of controlling matter on an atomic and molecular scale. In the animal medicine industry, nanotechnology is used to improve diagnosis, treatment, animal growth promotion, and production. Nanoparticles are mainly used as alternative antimicrobial agents to reduce the use of antibiotics and improve the detection of pathogenic bacteria. They are also used as drug delivery agents for new drugs and vaccine candidates to improve their characteristics and performance and to reduce drug resistance in animal organisms. Major companies in the animal medicine market include Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co, Evonik Industries AG, Patterson Companies Inc., Ceva Animal Health LLC – Biomune, Phirbo Animal Health, Dechra Pharmaceuticals, Virbac Group, and Vetoquinol S.A. North America was the largest region in animal medicine market in 2022. Asia-Pacific was the second-largest region in the animal medicine market. The regions covered in the animal medicine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the animal medicine market include Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The animal medicine market consists of sales of procuring drugs to shield against external parasites like fleas, ticks, and heartworms (intestinal parasites). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global animal medicine market is segmented - 1) By Type: Veterinary Pharmaceuticals, Feed Additives 2) By Type of Animal: Livestock, Companion Animals 3) By End-Use: Veterinary Hospitals, Pharmacies And Drug Stores, Veterinary Clinics Subsegments Covered: Veterinary Vaccines, Veterinary Antibiotics, Veterinary Parasiticides, Other Veterinary Pharmaceuticals, Medical Feed Additives, Nutritional Feed Additives

The animal antibiotics and antimicrobials refer to veterinary medications that work against bacteria or microorganisms by either killing bacteria/microorganisms or limiting their development and multiplication. These medications are used in animals to treat clinical diseases, to prevent or control common disease events, and enhance animal growth. The main types of animal antibiotics and antimicrobials include tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobials and antibiotics. Tetracyclines are bacteriostatic, and their mechanism of action is through reversible binding of bacterial 30S ribosomes and alteration of bacterial cytoplasmic membrane. They are also referred to as oral medication used in treatment of bacterial infections due to aerobic, gram-negative bacteria, mycoplasma, and others. These are delivered in different forms including premixes, oral powder, oral solutions, injection, and others. These medications are used in both companion and food-producing animals. The animal antibiotics and antimicrobials market research report is one of a series of new reports from The Business Research Company that provides animal antibiotics and antimicrobials market statistics, including animal antibiotics and antimicrobials industry global market size, regional shares, competitors with a animal antibiotics and antimicrobials market share, detailed animal antibiotics and antimicrobials market segments, market trends and opportunities, and any further data you may need to thrive in the animal antibiotics and antimicrobials industry. This animal antibiotics and antimicrobials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global animal antibiotics and antimicrobials market size grew from $4.68 billion in 2022 to $5.07 billion in 2023 at a compound annual growth rate (CAGR) of 8.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The animal antibiotics and antimicrobials market size is expected to grow to $6.95 billion in 2027 at a CAGR of 8.2%. Rising demand for animal-derived food products is driving the growth of the animal antibiotics and antimicrobials market. Animal-derived food products such as milk, eggs, meat, and other act a major source of nutrition and plays a prominent role in human diet. The companies/institutions involved in production of animal-derived foods are focusing on developing healthy herd or disease-free herd through utilization of animal antibiotics and antimicrobials on precautionary basis. According to the data published in the Packaged Facts report on Global Meat & Poultry trends, global meat and poultry consumption is expected to reach 313 million metric tons in 2023, at a year-on-year growth rate of 1.4%. Therefore, increasing demand for animal-derived food products is expected to boost demand for animal antibiotics and antimicrobials during forecast period. Strategic partnership is a key trend gaining popularity in the animal antibiotics and antimicrobials market. The companies operating in animal antibiotics and antimicrobial sector are entering into strategic partnerships with relevant industry players for the research and development of innovative animal antibiotics and antimicrobials. In May 2022, Gnubiotics Sciences, a Switzerland-based biotech company working to solve microbiome-related health conditions in humans and animals, entered into a partnership with ADM, a US-based developer of human and health nutrition solutions, for commercializing new microbiome solutions for companion animal health and wellbeing. In August 2020, Elanco, a US-based pharmaceutical company that manufacturers medicines and vaccinations for pets and livestock, acquired Bayer’s animal health business unit for $6.89 billion. With this acquisition, Elanco will improve its research and development pipeline and broaden its range of animal health products. Bayer’s animal health business unit is a Germany-based pharmaceutical and life sciences company. Major players in the animal antibiotics and antimicrobials market are Boehringer Ingelheim, Zoetis Inc., Elanco Animal Health, Merck & Co. Inc., Phibro Animal Health, Vetoquinol SA, Lutim Pharma, Ceva Santé Animale, Dechra Pharmaceuticals PLC., Kyoritsu Seiyaku, Huvepharma Inc., Zydus, Indian Immunologicals Pvt. Ltd., Bayer Animal Health, Virbac Animal Health, and Phibro Animal Health Corp. North America was the largest region in the animal antibiotics and antimicrobials market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal antibiotics and antimicrobials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the animal antibiotics and antimicrobials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The animal antibiotics and antimicrobials market consists of sales of glycopeptides, ß-Lactam antibiotics, and polymixins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global animal antibiotics and antimicrobials market is segmented - 1) By Type of Product: Tetracyclines, Penicillins, Sulfonamides, Macrolides, Aminoglycosides, Lincosamides, Fluoroquinolones, Cephalosporins, Other Antimicrobials and Antibiotics 2) By Mode of Delivery: Premixes, Oral Powder, Oral Solution, Injection, Other Modes of Delivery 3) By Animal Type: Food-Producing Animals, Companion Animals

The animal-based protein supplements refer to dietary supplements that are used to complete the daily requirement of protein for the body and to enhance muscle synthesis and growth of lean muscle mass. Animal-based protein supplements are protein supplements extracted from animal sources, including eggs, milk, and collagen. Animal-based protein supplements are considered an excellent source of protein since they have all the essential amino acids and are considered a complete protein. They also have a more neutral taste and are blended easily. The main product types of animal-based protein supplements are supplements, protein powder, protein bars, ready-to-drink, and others. Protein powders are a convenient way of consuming protein and can be enriched with added enzymes, vitamins, and minerals to improve their nutritional value. The different raw materials include whey, casein, eggs, fish, and others that are used in pharmaceuticals and nutraceuticals, food and beverages, infant formulations, cosmetics and personal care, animal feed, and dietary supplements. It is distributed through several channels such as supermarkets and hypermarkets, online stores, chemists' or drugstores, specialty stores, and others. The animal-based protein supplements market research report is one of a series of new reports from The Business Research Company that provides animal-based protein supplements market statistics, including global market size, regional shares, competitors with an animal-based protein supplements market share, detailed animal-based protein supplements market segments, market trends and opportunities, and any further data you may need to thrive in the animal-based protein supplements industry. This animal-based protein supplements market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global animal based protein supplements market size grew from $25.59 billion in 2022 to $28.02 billion in 2023 at a compound annual growth rate (CAGR) of 9.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The animal based protein supplements market size is expected to grow to $40.07 billion in 2027 at a CAGR of 9.4%. The increasing number of health-conscious consumers is expected to drive the growth of the animal-based protein supplement market going forward. The number of people focusing on their health and nutrition has been increasing globally in recent years, due to which people are more aware of completing the daily protein requirement and its importance in bodily functions. To complete the protein requirement, people are moving towards animal-based protein supplements, which in turn are resulting in the growth of the demand for animal-based protein supplements. For instance, in March 2022, according to Avendus Capital, an India-based financial services firm, consumers who are concerned about their health are predicted to increase from 108 million in 2020 to 176 million in 2026. In addition, after the pandemic, 70% of Indians said they would prioritize dietary changes to improve their overall health. Therefore, the increasing number of health-conscious consumers is driving the demand for animal-based protein supplements. Product innovations have emerged as the key trend gaining popularity in the animal-based protein supplement market. Major companies operating in the animal-based protein supplement market are focused on developing new technological solutions to strengthen their position in the market. For instance, in 2021, GoodSport Nutrition, a US-based healthy sports drink manufacturing company, launched the GoodSport sports drink, a first-of-its-kind natural sports drink made from 97% dairy. The drink delivers three times more electrolytes and 33% less sugar than a conventional sports drink. According to the firm, research has shown that milk hydrates more effectively than other sports beverages and water. In February 2022, Nestlé Health Science, a Switzerland-based nutrition company, acquired Vital Proteins for an undisclosed amount. The acquisition would help Nestlé add another brand to its vitamin, mineral, supplement, and wellness portfolio. Vital Proteins is a US-based producer and marketer of animal collagen-based protein supplements. Major players in the animal-based protein supplements market are Glanbia plc, Abbott Laboratories, CytoSport Inc., MusclePharm Corporation, Iovate Health Sciences International Inc., AMCO Proteins, WOODBOLT DISTRIBUTION LLC, Quest Nutrition, NOW Foods, Transparent Labs, The Bountiful Company, Dymatize Enterprises LLC, BPI Sports LLC, JymSupplementScience, RSP Nutrition, and International Dehydrated Foods Inc., North America was the largest region in the animal-based protein supplements market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal-based protein supplements market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the animal-based protein supplements market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The animal-based protein supplements market consists of sales of egg white protein, collagen, and beef protein isolate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global animal based protein supplements market is segmented - 1) By Product: Protein Powder, Protein Bars, Ready-To-Drink, Other Products 2) By Raw Materials: Whey, Casein, Egg, Fish, Other Raw Materials 3) By Application: Pharmaceuticals and Nutraceuticals, Food and Beverages, Infant Formulations, Cosmetics and Personal Care, Animal Feed, And Dietary Supplements 4) By Distribution Channel: Supermarkets And Hypermarkets, Online Stores, Chemists or Drugstores, Specialty Stores, Other Distribution Channels

The companion animal arthritis refers to a condition involving inflammation of one or more joints in companion animals such as cats, dogs, and other exotic animals. Companion animal arthritis develops in the bones when the cartilage between joints becomes rougher and more worn, forcing the bone surfaces to rub against one another. The main type of companion animal arthritis are dogs, cats, and others types. The dogs companion animal arthritis are used for controlling pain and inflammation in dogs. Dogs are domesticated canines (Canis familiaris) that are usually kept as pets or trained for hunting, guarding individuals or property. The companion animal arthritis indication are osteoarthritis and, other arthritis, that are treatment through medication, supplements and other treatment, which are sold and distributed through veterinary hospitals and clinics, retail pharmacies, online stores, and others. The companion animal arthritis market research report is one of a series of new reports from The Business Research Company that provides companion animal arthritis market statistics, including companion animal arthritis industry global market size, regional shares, competitors with a companion animal arthritis market share, detailed companion animal arthritis market segments, market trends and opportunities, and any further data you may need to thrive in the companion animal arthritis industry. This companion animal arthritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global companion animal arthritis market size grew from $3.09 billion in 2022 to $3.47 billion in 2023 at a compound annual growth rate (CAGR) of 12.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The companion animal arthritis market size is expected to grow to $4.72 billion in 2027 at a CAGR of 8.0%. Rising trend of pet adoption is expected to propel the growth of companion animal arthritis market. Pet adoption helps reduce stress, anxiety, depression, and so on. Pet adoption is a method of getting a dog, cat, and other exotic animals that their prior owners have given up to a shelter or rescue rather than getting one from a pet shop, breeder, or another individual. Pets face the risk of developing arthritis once they start getting into old age. For instance, according to a survey conducted by, The American Pet Products Association, a US-based not-for-profit industry association, approximately half of british homes with pets acquired at least one new animal while the country was in lockdown, while 11.3 million Americans acquired new pets during the pandemic. Additionally, in the survey, 16% of Generation Z respondents and 13% of millennials stated they had adopted a new pet during the pandemic. Therefore, the rising trend of pet adoption contributes significantly to the growth of the companion animal arthritis market. Technological innovation is a key trend in the companion animal arthritis market. Technological innovation benefits people by improving productivity and giving them access to freshly produced better goods and services, which raise the general standard. Major players in the industry are using monoclonal antibody therapy to treat companion animal arthritis. Monoclonal antibody therapy is used on companion animals to treat arthritis, immune-mediated disorders, chronic pain, and others. Monoclonal antibodies are antibodies produced by immune cells that are identical clones of a single parent cell. For instance, In April 2021, Zoetis, a US-based pharmaceutical company, launched LIBRELA® and SOLENSIA® in European Union, United Kingdom, and Switzerland to prevent arthritis pain in cats and dogs using monoclonal antibody therapy. It works similarly to naturally produced antibodies, with little involvement of the liver or kidneys in their metabolism and removal of gastrointestinal impact. In September 2022, Zoetis, a US-based animal health company, acquired NewMetrica for an undisclosed amount. This transaction would enhance Zoetis' capacities throughout the continuum of care, expand our grasp of quality-of-life evaluations, and result in a more profound comprehension of an animal's well-being. NewMetrica is a UK-based provider of scientifically-developed instruments to measure quality-of-life in animals such as canine arthritis. Major players in the companion animal arthritis market are Zoetis, Virbac, Elanco, Boehringer Ingelheim International GmbH, Ceva Santé Animale, Dechra Pharmaceuticals PLC, Vetoquinol, NexGen Pharmaceuticals, Norbrook, Eltech K-Laser s.r.l., Companion Animal Health, Canine Arthritis Management, Bioiberica, Assisi Animal Health and Exubrion Therapeutics Inc., North America was the largest region in the companion animal arthritis market in 2022. The regions covered in the companion animal arthritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the companion animal arthritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The companion animal arthritis market includes revenues earned by entities by NSAIDs, monoclonal antibiotics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global companion animal arthritis market is segmented - 1) By Type: Dogs, Cats, Other Types 2) By Indication: Osteoarthritis, Other Arthritis 3) By Treatment: Medication, Supplements, Other Treatments 4) By Distribution Channel: Veterinary Hospitals And Clinics, Retail Pharmacies, Online Stores, Other Distribution Channels

Veterinary vaccine refers to a biological preparation that stimulates the immune response of an animal against disease in order to reduce animal suffering and the transmission of microorganisms in the animal population and enhance the immunity power of animals by improving animal health, which also prevents the transmission of diseases from animals to humans. The various types of veterinary vaccines are live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, and other vaccine types. Inactivated vaccines differ from live but attenuated vaccines as they are made up of dead, or inactivated, viruses and bacteria. The disease types are anaplasmosis, canine parvovirus, foot and mouth disease, Newcastle disease, distemper disease, influenza, and porcine reproductive and respiratory syndrome, and the application areas include livestock vaccines, and companion animal vaccines. The veterinary vaccines research report is one of a series of new reports from The Business Research Company that provides veterinary vaccines statistics, including veterinary vaccines industry global market size, regional shares, competitors with veterinary vaccines share, detailed veterinary vaccines segments, market trends and opportunities, and any further data you may need to thrive in the veterinary vaccines industry. The veterinary vaccines research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global veterinary vaccines market size will grow from $10.89 billion in 2022 to $11.57 billion in 2023 at a compound annual growth rate (CAGR) of 6.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global veterinary vaccines market size is expected to grow to $14.2 billion in 2027 at a CAGR of 5.3%. The increase in the number of animals suffering from a range of diseases is increasing the demand for vaccines to prevent and treat such diseases, thus driving the veterinary vaccines market According to the estimates from a report by the Animal and Plant Health Agency, a total of 3289 new TB herd incidents were detected in England Bovine tuberculosis is a chronic disease that usually affects animals such as cattle, but it can affect all mammals, causing a general state of illness, coughing and eventually leading to death. However, the disease can be treated with specific antibiotics that kill the TB bacteria. This rising prevalence of diseases in animals is expected to drive the veterinary vaccines market during the forecast period. High storage costs are acting as a major restraint on the growth of the veterinary vaccine market. Improper storage conditions and delays in shipping can cause vaccines to lose their desired immune properties. For example, during transportation, vaccines can undergo biodegradation, if they are not transported within the required temperature limits. Thus, special care is required for the transportation of the vaccines to maintain their efficiency, which increases the storage and transportation costs for the vaccines. According to a report published by the National Institute of Standards and Technology (NIST), approximately 35% of vaccines lost their potency during the shipment, as they were stored at abnormal temperatures. Thus, high storage costs for vaccines are expected to result in additional costs for manufacturing companies and limit the growth of the market. Companies in the veterinary vaccines market are increasingly looking for strategic partnerships and collaborations to enter into new geographies and to share research and development projects. For example, in 2020, the Pirbright Institute, a UK-based animal disease research institute, partnered with ECO Animal Health, a UK-based pharmaceutical company, and the Vaccine Group (TVG) to develop porcine respiratory and reproductive syndrome virus (PRRSV) vaccines. The vaccine group is a biotechnology company that develops animal vaccines and is based in Plymouth, UK. Similarly, MSD Animal Health, a division of Merck & Co with headquarters in the US, made a strategic partnership with Vinovo. This partnership will help MSD Animal Health to combine its unique broad vaccine product line and Vinovo’s vaccine delivery system to the vaccination process, thus improving bird welfare, and reducing vaccine reactions. Also, Wageningen bio veterinary research made a strategic alliance with Ceva with headquarters in Switzerland, to improve their Research on the global threat of emerging and reemerging diseases for animals. The veterinary vaccines market is regulated by authorities such as the European Medical Agency and the US Center for Veterinary Biologics. For instance, veterinary vaccine companies in Europe are required to adhere to European technical requirements mentioned in Annex 1, Title II, of Directive 2001/82/EC, as amended by Directive 2009/9/EC, and the European Pharmacopoeia (Ph. Eur.). According to these regulations, veterinary vaccines are required to undergo safety tests before getting approval, where vaccines are classified into activated vaccines and inactivated vaccines. For inactivated vaccines, each batch of vaccines should have a dose that is double the standard dose. In inactivated vaccines, each batch of vaccines should be ten times the standard dose for the active vaccines. Activated vaccines are usually tested by in vitro titration, while serological tests are commonly used for inactivated vaccines. Major players in the veterinary vaccines market are Boehringer Ingelheim GmbH, Merck Animal Health, Zoetis Inc., Eli Lilly and Company, Bayer AG (Bayer Animal Health), CevaSantéAnimale, Virbac, Biovac, Zoetis Animal Healthcare, and Hester Biosciences Ltd. North America was the largest region in the veterinary vaccines market in 2022. Asia-Pacific was the second-largest region in the global veterinary vaccines market. The regions covered in the global veterinary vaccines report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary vaccines market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The veterinary vaccines market consists of sales of messenger RNA vaccine, viral vector vaccine, and subunit vaccine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global veterinary vaccines market is segmented - 1) By Application: Livestock Vaccines, Companion Animal Vaccines 2) By Vaccine Type: Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Other Vaccine Types 3) By Disease Type: Anaplasmosis, Canine Parvovirus, Foot And Mouth Disease, Newcastle Disease, Distemper Disease, Influenza, Porcine Reproductive And Respiratory Syndrome (PRRS)

Veterinary antibiotics refer to a class of animal medications that are used to treat infectious disease in animals by killing microorganisms such as bacteria and parasites by inhibiting the growth of their cell walls to fight infections and diseases in animals caused by bacteria and improve the animals' health conditions. The main product types of veterinary antibiotics include anti-parasitic, anti-bacterial, non-steroidal anti-inflammatory drugs, and other products. Non-steroidal anti-inflammatory drugs (NSAIDs) act as a bridge between the production and activity of prostaglandins (enzymes) implicated in inflammation. Approved veterinary NSAIDs are used in companion animal care to reduce the pain and swelling linked with osteoarthritis in dogs and horses. The administration of veterinary antibiotics includes premixes, injections, oral powders, oral solutions, and other administrations used on farm animals and companion animals. The veterinary antibiotics research report is one of a series of new reports from The Business Research Company that provides veterinary antibiotics statistics, including veterinary antibiotics industry global market size, regional shares, competitors with veterinary antibiotics share, detailed veterinary antibiotics segments, market trends and opportunities, and any further data you may need to thrive in the veterinary antibiotics industry. The veterinary antibiotics research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global veterinary antibiotics market size will grow from $1.86 billion in 2022 to $2.02 billion in 2023 at a compound annual growth rate (CAGR) of 8.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global veterinary antibiotics market size is expected to grow to $2.7 billion in 2027 at a CAGR of 7.5%. An increase in the number of zoonotic diseases is driving the veterinary antibiotics market. Zoonotic diseases are infectious diseases caused by microscopic organisms, infections, and parasites that spread between animals and humans. Two of the most common zoonotic pathogens, salmonella and campylobacter, are present in the intestines of these animals. Zoonotic diseases are also a potential threat to humans as they get transferred through the food chain. A study conducted by the FoodNet (Centers for Disease Control and Prevention, USA) found that 24,484 foodborne illnesses, 5,677 hospitalizations, and 122 deaths are caused by zoonotic diseases. In addition, the highest incidences per 100,000 people in the USA are caused by infectious diseases such as campylobacter, salmonella, and shigella. Therefore, there is a need to diagnose these diseases in animals at an early stage, which is a major driver of the veterinary antibiotics market. The rising threat of antibiotic resistance is a major restraint for the veterinary antibiotics market. Antibiotic resistance in animals refers to the ability of a microbe to withstand the impact of an antibiotic that once successfully treated infections caused by the same type of microbe. This can be a result of using antibiotics more than the prescribed limit. In this regard, the European Union (EU) has approved various restrictions on veterinary antibiotics, including a ban on antibiotics for animals and prohibiting the usage of antimicrobials in food, which is restricting the growth of the veterinary antibiotics market. Increasing collaboration between companies is an emerging trend in the veterinary antibiotics market. Collaboration offers companies the opportunity to combine technologies and a wide range, more diversified products to work with, and it also improves the quality of the antibiotics and the speed at which they are produced. Therefore, companies in the veterinary antibiotics market are focusing on collaborations. For instance, in September 2022, GlobalVetLink, a US-based provider of software services and informatics solutions in the field of animals, collaborated with Veterinary Innovative Partners to install GlobalVetLink Compliance Assistant, a thorough SaaS platform developed to simplify animal health. The veterinary antibiotics prescription drugs market is regulated by Section 503(f) of the Food, Drug, and Cosmetic Act of FDA. According to this law, the veterinary antibiotic drug labels are mandated to include a caution statement that states that these drugs can only be used with the permission of a licenced veterinarian. The sale and use of antibiotic prescription drugs without a prescription is usually reported to the FDA and strict action is taken based on it. Hence, regulations such as these would regulate veterinary antibiotic manufacturers and sellers. Major players in the veterinary antibiotics market are Bayer AG, Boehringer Ingelheim GmbH, CevaSanteAnimale, Eli Lilly Company, ElanCo., Merck & Co., Sanofi, Virbac, Zoetis, and Crystal Pharma. North America was the largest region in the veterinary antibiotics market in 2022. Asia-Pacific was the second-largest region in the global veterinary antibiotics market. The regions covered in the global veterinary antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary antibiotics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The veterinary antibiotics market consists of sales of antivirals, antiprotozoals, antifungals, aminoglycosides, beta-lactams, fluoroquinolones, glycopeptides, and lipopeptides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global veterinary antibiotics market is segmented - 1) By Product: Anti-Parasitic, Anti-Bacterial, Non-Steroidal Anti-Inflammatory Drug, Other Products 2) By End User: Farm Animals, Companion Animals 3) By Administration: Premixes, Injections, Oral Powders, Oral Solutions, Other Administration

Veterinary healthcare refers to a healthcare service that is associated with the diagnosis, treatment, and prevention of diseases in animals and the duties of an individual whose job it is to provide medical care for animals who are ill or injured, or to describe such care to reduce transmission of infectious disease from one pet to another. The main types of veterinary healthcare are veterinary services, veterinary medical equipment, animal medicine and are used for the animals such as dogs and cats, horses, ruminants, swine, poultry, and other animals. Veterinary services refer to the healthcare services that are provided to the animals. The products include instruments/equipment, disposables. The veterinary healthcare research report is one of a series of new reports from The Business Research Company that provides veterinary healthcare statistics, including veterinary healthcare industry global market size, regional shares, competitors with veterinary healthcare share, detailed veterinary healthcare segments, market trends and opportunities, and any further data you may need to thrive in the veterinary healthcare industry. This veterinary healthcare research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global veterinary healthcare market grew from $180.32 billion in 2022 to $195.77 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, and affecting many markets across the globe. The veterinary healthcare market is expected to grow from $261.48 billion in 2027 at a CAGR of 7.5%. Global meat production is expected to rise in the forecast period, supporting the growth of the veterinary healthcare market. According to the US Department of Agriculture, in 2020, the beef production in the USA reached27.5 billion pounds, the highest production volume registered in the country. Rising meat production is especially prominent in developing countries such as China, India, and Brazil, where increasing populations and rising income levels are stimulating the demand for meat products. By 2027, the production of meat and poultry in emerging markets is expected to increase by 76%. By 2050, China's meat imports are expected to grow by over 3,500% to $150 billion as consumption of chicken, pork, and beef will surge due to the country's rising middle class. The rising production of meat products supported by the growing population will increase the demand for feed additives in the livestock industry, driving the veterinary healthcare market. The outbreak of COVID-19 disease (COVID-19) has acted as a massive restraint on the veterinary healthcare market in 2020 as supply chains were disrupted due to trade restrictions and consumption declined due to lockdowns imposed by governments globally. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China, and spread globally, including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of "lock down" and the outbreak hurting businesses throughout 2020 and into 2021. However, it is expected that the veterinary healthcare market will recover from the shock over the forecast period as it is a 'black swan" event and not related to ongoing or fundamental weaknesses in the market or the global economy. Nanotechnology is increasingly gaining traction in the animal medicine market as a substitute for veterinary antibiotics to tackle antibiotic resistance. Nanotechnology is the study of controlling matter on an atomic and molecular scale. In the animal medicine industry is used to improve diagnosis, treatment, animal growth promotion, and production. Nanoparticles are mainly used as alternative antimicrobial agents to reduce the use of antibiotics and improve the detection of pathogenic bacteria. They are also used as drug delivery agents for new drugs and vaccine candidates to improve their characteristics and performance, and to reduce drug resistance in animal organisms. Major companies in the veterinary healthcare market include Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co, IDEXX Laboratories, Evonik Industries AG, Patterson Companies Inc., Ceva Animal Health LLC – Biomune; Pets at Home Group PLC, National Veterinary Associates, and Phirbo Animal Health. North America was the largest region in the veterinary healthcare market in 2022. Asia-Pacific was the second-largest region in the veterinary healthcare market. The regions covered in the veterinary healthcare report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary healthcare market include Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The veterinary healthcare market includes revenues earned by entities by providing treatment for diseases that influence the health of domestic and wild animals and must be prevented, controlled, diagnosed, and treated, along with the human transmission of animal diseases.The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global veterinary healthcare market is segmented - 1) By Type: Veterinary Services, Veterinary Medical Equipment, Animal Medicine 2) By Product: Instruments/Equipment, Disposables 3) By Animal Type: Dogs and Cats, Horses, Ruminants, Swine, Poultry, Other Animals Subsegments Covered: Animal Hospitals And Veterinary Clinics, Veterinary Laboratory Testing Services, Veterinary Diagnostic Equipment, Veterinary Anesthesia Equipment, Veterinary Patient Monitoring Equipment, Other Veterinary Medical Equipment, Veterinary Pharmaceuticals, Feed Additives